Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2023 10:19 ET | Source: Transparency Market Research

North America Safety Pen Needles Market Worth USD 1.17 billion by 2031, Registering at a CAGR of 6.4% Says Transparency Market Research

Wilmington, Delaware, United States, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global North America safety pen needles market is projected to flourish at a CAGR of...
May 23, 2023 10:03 ET | Source: Market.Us

8.1% CAGR of Human Growth Hormone Market to Reach USD 7.3 Billion by 2032, Says Market.us Research Study

New York, May 23, 2023 (GLOBE NEWSWIRE) -- The Human Growth Hormone Market in terms of revenue was estimated to be worth USD 3.4 Bn in 2022 and is poised to reach USD 7.3 bn by 2032, growing at a...
November 29, 2022 09:30 ET | Source: Market Research Future

Growth Hormone Market Size Worth USD 5800 Million by 2030 at 7.60% CAGR – Report by Market Research Future (MRFR)

New York, USA, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Growth Hormone Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Growth Hormone Market Information By...
September 30, 2022 09:30 ET | Source: Transparency Market Research

Safety Pen Needles Market in North America to Exceed Value of US$ 1.17 Bn by 2031, States TMR Analysis

Wilmington, Delaware, United States, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The safety pen needles market in North America is prognosticated to surpass a value of US$...
April 29, 2021 07:00 ET | Source: Global Market Insights, Inc

Growth Hormone Market revenue to cross USD 5.3 Bn by 2027: Global Market Insights Inc.

Selbyville, Delaware, April 29, 2021 (GLOBE NEWSWIRE) -- According to latest report “Growth Hormone Market by Product (Powder, Solvent), Application (Growth Hormone Deficiency, Idiopathic Short...
January 07, 2019 09:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches

COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...